Results 81 to 90 of about 13,638 (219)

Gamma‐irradiated Newcastle disease virus: an alternative inactivated oncolytic virotherapy

Immunology &Cell Biology, EarlyView.
To overcome biological risks associated with using live NDV as an oncolytic therapy, we developed gamma‐NDV as a safer alternative. Using a murine model for skin cancer, we show that intratumor administration of gamma‐NDV outperformed live‐NDV in terms of reducing tumor growth and improving overall animal survival. Abstract Newcastle disease virus (NDV)
Eve V Kennedy, Yimin Chuah, Amal H Mostafa, Chloe J Gates, Jade Foeng, Todd S Norton, Shaun R McColl, Iain Comerford, Justin B Davies, Farhid Hemmatzadeh, Mohammed Alsharifi   +10 more
wiley   +1 more source

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

SAGE Open Medical Case Reports, 2020
Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia.
Vladimirs Sorokins, Andra Tilgase, Evija Olmane, Sergejs Isajevs, Tatjana Zablocka, Agnija Rasa, Pēteris Alberts   +6 more
doaj   +1 more source

Isocitrate Dehydrogenase‐Mutant Astrocytomas: Risk Stratification and Therapeutic Advance

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract synthesizes the core logic of our revised review by linking integrated diagnosis, risk stratification, and trajectory‐based management in IDH‐mutant astrocytomas across CNS WHO Grades 2–4. It highlights lineage‐defining molecular classification (IDH mutation with core co‐alterations), integrated histomolecular grading, and key ...
Shepeng Wei, Xuxu Xu, Jing Bao, Zhenjiang Pan   +3 more
wiley   +1 more source

The Hitchhiker's Guide to Virotherapy

Oncotarget, 2012
In contrast to most other cancer therapies, early research with oncolytic viruses (OV) tended to use direct or intratumoural routes of administration, initially motivated by concerns that the major limitation of intravenous delivery would be immune attack against the viruses, whether by complement, cytokine or most critically neutralising antibodies ...
Donnelly, O, Vile, R, Pandha, H, Harrington, K, Melcher, A   +4 more
openaire   +4 more sources

Oncolytic polio virotherapy of cancer [PDF]

Cancer, 2014
Recently, the century‐old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late‐stage clinical trials in a variety of cancers. Although originally prized for their direct tumor cytotoxicity (oncolytic virotherapy), recently, the proinflammatory and immunogenic effects ...
Michael C, Brown, Elena Y, Dobrikova, Mikhail I, Dobrikov, Ross W, Walton, Sarah L, Gemberling, Smita K, Nair, Annick, Desjardins, John H, Sampson, Henry S, Friedman, Allan H, Friedman, Douglas S, Tyler, Darell D, Bigner, Matthias, Gromeier   +12 more
openaire   +2 more sources

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model

Frontiers in Immunology, 2023
IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB.
Rūta Veinalde, Gemma Pidelaserra-Martí, Gemma Pidelaserra-Martí, Gemma Pidelaserra-Martí, Coline Moulin, Coline Moulin, Chin Leng Tan, Chin Leng Tan, Theresa E. Schäfer, Na Kang, Claudia R. Ball, Claudia R. Ball, Jonas Leichsenring, Jonas Leichsenring, Albrecht Stenzinger, Lars Kaderali, Dirk Jäger, Dirk Jäger, Guy Ungerechts, Guy Ungerechts, Christine E. Engeland, Christine E. Engeland, Christine E. Engeland   +22 more
doaj   +1 more source

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +1 more source

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

Journal of Hematology & Oncology, 2021
Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far ...
Johannes P. W. Heidbuechel, Christine E. Engeland   +1 more
doaj   +1 more source

ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report

American Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of choroidal melanoma treated with Rigvir® virotherapy in an adjuvant setting. Observations: A female patient born in 1956 presented with a small choroidal melanoma in October 2007. 34 months after transpupillary thermotherapy
Inta Jaunalksne, Linda Brokāne, Donatas Petroška, Agnija Rasa, Pēteris Alberts   +4 more
doaj   +1 more source

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice [PDF]

, 2008
BACKGROUND: The NV1020 oncolytic herpes simplex virus type-1 has shown significant promise for the treatment of many different types of tumors in experimental animal models and human trials. Previously, we described the construction and use of the NV1020-
Israyelyan, Anna, Chouljenko, Vladimir N, Baghian, Abolghasem, David, Andrew T, Kearney, Michael T, Kousoulas, Konstantin G   +5 more
core   +2 more sources